15 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
12 May 22
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
4:21pm
$2.0 million compared to $1.5 million for the same period in 2021. The increase in our R&D expenditures was primarily due to costs we incurred in our … and consulting costs. We allocated $829 thousand of non-cash compensation costs between our R&D and G&A expenses.
As of March 31, 2022, we had 15.8 million shares
8-K
PCSA
Processa Pharmaceuticals Inc
11 Apr 24
Regulation FD Disclosure
8:00am
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation Disclosure.
David Young, President, R&D for Processa
8-K
PCSA
Processa Pharmaceuticals Inc
5 Dec 23
Regulation FD Disclosure
5:18pm
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation Disclosure.
Dr. David Young, President R&D for Processa
8-K
PCSA
Processa Pharmaceuticals Inc
4 Apr 24
Regulation FD Disclosure
12:05pm
Generation Chemotherapy: Improved Treatment for More Patients” was held on April 3, 2024 at 10:55 AM ET. Dr. David Young, President R&D attended
8-K
PCSA
Processa Pharmaceuticals Inc
27 May 14
Departure of Directors or Certain Officers
12:00am
Financial Officer of LEHR, a green technology company and the world’s largest manufacturer of propane powered engines specialized in the R&D, manufacture
8-K
EX-99.1
qfxgbo whbou692jmj2
5 Mar 20
Processa Pharmaceuticals Announces Formation of Its Medical and Scientific Advisory Board
9:30am
8-K
EX-99.1
5z3mk
31 Mar 23
Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
8:30am
8-K
EX-99.1
fwp 3m4ljgtx6yro
12 Aug 22
Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
10:35am
8-K
EX-99.1
kvyft11q
8 Nov 22
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
4:07pm
- Prev
- 1
- Next